GlassScriptPhysician profile
Karla M Pray
NPI 1801153531
$8,221.56
in general payments reported to CMS, 2019-2025
31 companies · $1,376 in 2025
The $1,376 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $625 · 2022: $5,039 · 2023: $550 · 2024: $631 · 2025: $1,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.11 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,618.85 | 2021-2022 | |
| Eisai INC. | $321.59 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $311.76 | 2024-2025 | Iqirvo, Onivyde |
| Astrazeneca Pharmaceuticals LP | $278.04 | 2023-2025 | Imfinzi, Enhertu, Lynparza |
| Exact Sciences Corporation | $275.09 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.71 | 2021-2024 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $245.71 | 2021-2023 | Ocaliva |
| Boston Scientific Corporation | $197.96 | 2022 | |
| Mirum Pharmaceuticals, INC. | $188.42 | 2023-2025 | Livmarli |
| Exelixis INC. | $143.50 | 2023-2025 | Cabometyx |
| Abbvie INC. | $142.83 | 2021-2025 | |
| Janssen Biotech, INC. | $134.17 | 2025 | Rybrevant |
| Genentech USA, INC. | $131.25 | 2021 | |
| Intra-Sana Laboratories | $124.99 | 2022 | |
| Alnylam Pharmaceuticals INC. | $122.58 | 2024 | Givlaari |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $102.92 | 2022-2025 | Iclusig, Livtencity |
| Seagen INC. | $99.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $81.37 | 2025 | |
| Merck Sharp & Dohme LLC | $68.68 | 2025 | Lynparza, Welireg, Keytruda Qlex |
| Legend Biotech USA INC. | $51.46 | 2025 | Carvykti |
| Servier Pharmaceuticals LLC | $50.20 | 2025 | |
| Geron Corporation | $45.12 | 2025 | Rytelo |
| E.R. Squibb & Sons, L.L.C. | $39.53 | 2025 | Opdivo |
| Syndax Pharmaceuticals, INC. | $31.06 | 2025 | |
| Taiho Oncology, INC. | $26.42 | 2025 | |
| Sobi, INC | $25.79 | 2025 | |
| Lilly USA, LLC | $24.59 | 2025 | Jaypirca, Verzenio |
| Genzyme Corporation | $22.65 | 2025 | |
| Pfizer INC. | $18.34 | 2025 | |
| Glaxosmithkline, LLC. | $17.01 | 2025 | Ojjaara |
| Adc Therapeutics America, INC. | $16.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Pray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.